Benedikt Wiestler1, David Capper1, Volker Hovestadt1, Martin Sill1, David T W Jones1, Christian Hartmann1, Joerg Felsberg1, Michael Platten1, Wolfgang Feiden1, Kathy Keyvani1, Stefan M Pfister1, Otmar D Wiestler1, Richard Meyermann1, Guido Reifenberger1, Thorsten Pietsch1, Andreas von Deimling1, Michael Weller1, Wolfgang Wick1. 1. Department of Neurooncology (B.W., M.P., W.W.); Department of Neuropathology (D.C., A.v.D.); Department of Pediatric Oncology, Hematology, and Immunology, Heidelberg University Hospital (S.M.P.); Clinical Cooperation Units Neurooncology (B.W., W.W.), Neuropathology (D.C, A.v.D.); Neuroimmunology and Brain Tumor Immunology (M.P.); Division of Molecular Genetics (V.H.); Division of Biostatistics (M.S.); Division of Pediatric Neurooncology (S.M.P., D.T.W.J.), German Cancer Research Center (DKFZ), Heidelberg, Germany (O.D.W.) and German Cancer Consortium (DKTK); Department for Neuropathology, Institute of Pathology, Medical University of Hannover, Hannover, Germany (C.H.); Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany (J.F., G.R.); German Consortium for Translational Cancer Research (DKTK), Düsseldorf, Germany (M.P., G.R.); Institute for Neuropathology, Saarland University, 66421 Saarbrücken, Germany (W.F.); Institute for Neuropathology, University of Essen Medical School, Essen, Germany (K.K.); Institute for Neuropathology, University of Tübingen, Tübingen, Germany (R.M.); Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany (T.P.); Department of Neurology, University Hospital Zurich, Zürich, Switzerland (M.W.).
Abstract
BACKGROUND: Molecular biomarkers including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q codeletion, and O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation may improve prognostication and guide treatment decisions for patients with World Health Organization (WHO) anaplastic gliomas. At present, each marker is individually tested by distinct assays. Illumina Infinium HumanMethylation450 BeadChip arrays (HM450) enable the determination of large-scale methylation profiles and genome-wide DNA copy number changes. Algorithms have been developed to detect the glioma CpG island methylator phenotype (G-CIMP) associated with IDH1/2 mutation, 1p/19q codeletion, and MGMT promoter methylation using a single assay. METHODS: Here, we retrospectively investigated the diagnostic and prognostic performance of these algorithms in comparison to individual marker testing and patient outcome in the biomarker cohort (n = 115 patients) of the NOA-04 trial. RESULTS: Concordance for IDH and 1p/19q status was very high: In 92% of samples, the HM450 and reference data agreed. In discordant samples, survival analysis by Kaplan-Meier and Cox regression analyses suggested a more accurate assessment of biological phenotype by the HM450 analysis. The HM450-derived MGMT-STP27 model to calculate MGMT promoter methylation probability revealed this aberration in a significantly higher fraction of samples than conventional methylation-specific PCR, with 87 of 91 G-CIMP tumors predicted as MGMT promoter-methylated. Pyrosequencing of discordant samples confirmed the HM450 assessment in 14 of 17 cases. CONCLUSIONS: G-CIMP and 1p/19q codeletion are reliably detectable by HM450 analysis and are associated with prognosis in the NOA-04 trial. For MGMT, HM450 suggests promoter methylation in the vast majority of G-CIMP tumors, which is supported by pyrosequencing.
BACKGROUND: Molecular biomarkers including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q codeletion, and O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation may improve prognostication and guide treatment decisions for patients with World Health Organization (WHO) anaplastic gliomas. At present, each marker is individually tested by distinct assays. Illumina Infinium HumanMethylation450 BeadChip arrays (HM450) enable the determination of large-scale methylation profiles and genome-wide DNA copy number changes. Algorithms have been developed to detect the glioma CpG island methylator phenotype (G-CIMP) associated with IDH1/2 mutation, 1p/19q codeletion, and MGMT promoter methylation using a single assay. METHODS: Here, we retrospectively investigated the diagnostic and prognostic performance of these algorithms in comparison to individual marker testing and patient outcome in the biomarker cohort (n = 115 patients) of the NOA-04 trial. RESULTS: Concordance for IDH and 1p/19q status was very high: In 92% of samples, the HM450 and reference data agreed. In discordant samples, survival analysis by Kaplan-Meier and Cox regression analyses suggested a more accurate assessment of biological phenotype by the HM450 analysis. The HM450-derived MGMT-STP27 model to calculate MGMT promoter methylation probability revealed this aberration in a significantly higher fraction of samples than conventional methylation-specific PCR, with 87 of 91 G-CIMPtumors predicted as MGMT promoter-methylated. Pyrosequencing of discordant samples confirmed the HM450 assessment in 14 of 17 cases. CONCLUSIONS: G-CIMP and 1p/19q codeletion are reliably detectable by HM450 analysis and are associated with prognosis in the NOA-04 trial. For MGMT, HM450 suggests promoter methylation in the vast majority of G-CIMPtumors, which is supported by pyrosequencing.
Authors: Christian Koelsche; Felix Sahm; David Capper; David Reuss; Dominik Sturm; David T W Jones; Marcel Kool; Paul A Northcott; Benedikt Wiestler; Katja Böhmer; Jochen Meyer; Christian Mawrin; Christian Hartmann; Michel Mittelbronn; Michael Platten; Benjamin Brokinkel; Marcel Seiz; Christel Herold-Mende; Andreas Unterberg; Jens Schittenhelm; Michael Weller; Stefan Pfister; Wolfgang Wick; Andrey Korshunov; Andreas von Deimling Journal: Acta Neuropathol Date: 2013-10-24 Impact factor: 17.088
Authors: Benedikt Wiestler; David Capper; Tim Holland-Letz; Andrey Korshunov; Andreas von Deimling; Stefan Michael Pfister; Michael Platten; Michael Weller; Wolfgang Wick Journal: Acta Neuropathol Date: 2013-08-01 Impact factor: 17.088
Authors: Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert Journal: Brain Date: 2007-09-04 Impact factor: 13.501
Authors: Michael Weller; Stefan M Pfister; Wolfgang Wick; Monika E Hegi; Guido Reifenberger; Roger Stupp Journal: Lancet Oncol Date: 2013-08 Impact factor: 41.316
Authors: Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Wolfgang Wick; Christoph Meisner; Bettina Hentschel; Michael Platten; Alissa Schilling; Benedikt Wiestler; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Markus Weiler; Ghazaleh Tabatabai; Andreas von Deimling; Dorothee Gramatzki; Manfred Westphal; Gabriele Schackert; Markus Loeffler; Matthias Simon; Guido Reifenberger; Michael Weller Journal: Neurology Date: 2013-09-25 Impact factor: 9.910
Authors: Volker Hovestadt; Marc Remke; Marcel Kool; Torsten Pietsch; Paul A Northcott; Roger Fischer; Florence M G Cavalli; Vijay Ramaswamy; Marc Zapatka; Guido Reifenberger; Stefan Rutkowski; Matthias Schick; Melanie Bewerunge-Hudler; Andrey Korshunov; Peter Lichter; Michael D Taylor; Stefan M Pfister; David T W Jones Journal: Acta Neuropathol Date: 2013-05-14 Impact factor: 17.088
Authors: Veronique Frattini; Vladimir Trifonov; Joseph Minhow Chan; Angelica Castano; Marie Lia; Francesco Abate; Stephen T Keir; Alan X Ji; Pietro Zoppoli; Francesco Niola; Carla Danussi; Igor Dolgalev; Paola Porrati; Serena Pellegatta; Adriana Heguy; Gaurav Gupta; David J Pisapia; Peter Canoll; Jeffrey N Bruce; Roger E McLendon; Hai Yan; Ken Aldape; Gaetano Finocchiaro; Tom Mikkelsen; Gilbert G Privé; Darell D Bigner; Anna Lasorella; Raul Rabadan; Antonio Iavarone Journal: Nat Genet Date: 2013-08-05 Impact factor: 38.330
Authors: Elke Pfaff; Tobias Kessler; Gnana Prakash Balasubramanian; Anne Berberich; Daniel Schrimpf; Antje Wick; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; David Capper; Irini Schenkel; Andreas Eisenmenger; Susan Dettmer; Benedikt Brors; Michael Platten; Stefan M Pfister; Andreas von Deimling; David T W Jones; Wolfgang Wick; Felix Sahm Journal: Neuro Oncol Date: 2018-05-18 Impact factor: 12.300
Authors: Tathiane M Malta; Camila F de Souza; Thais S Sabedot; Tiago C Silva; Maritza S Mosella; Steven N Kalkanis; James Snyder; Ana Valeria B Castro; Houtan Noushmehr Journal: Neuro Oncol Date: 2018-04-09 Impact factor: 12.300
Authors: Alexander Schramm; Johannes Köster; Yassen Assenov; Kristina Althoff; Martin Peifer; Ellen Mahlow; Andrea Odersky; Daniela Beisser; Corinna Ernst; Anton G Henssen; Harald Stephan; Christopher Schröder; Lukas Heukamp; Anne Engesser; Yvonne Kahlert; Jessica Theissen; Barbara Hero; Frederik Roels; Janine Altmüller; Peter Nürnberg; Kathy Astrahantseff; Christian Gloeckner; Katleen De Preter; Christoph Plass; Sangkyun Lee; Holger N Lode; Kai-Oliver Henrich; Moritz Gartlgruber; Frank Speleman; Peter Schmezer; Frank Westermann; Sven Rahmann; Matthias Fischer; Angelika Eggert; Johannes H Schulte Journal: Nat Genet Date: 2015-06-29 Impact factor: 38.330
Authors: Antje Wick; Tobias Kessler; Michael Platten; Christoph Meisner; Michael Bamberg; Ulrich Herrlinger; Jörg Felsberg; Astrid Weyerbrock; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Jan Vesper; Jürgen Debus; Jürgen Meixensberger; Ralf Ketter; Caroline Hertler; Regine Mayer-Steinacker; Sarah Weisang; Hanna Bölting; David Reuss; Guido Reifenberger; Felix Sahm; Andreas von Deimling; Michael Weller; Wolfgang Wick Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Wolfgang Wick; Patrick Roth; Christian Hartmann; Peter Hau; Makoto Nakamura; Florian Stockhammer; Michael C Sabel; Antje Wick; Susanne Koeppen; Ralf Ketter; Peter Vajkoczy; Ilker Eyupoglu; Rolf Kalff; Torsten Pietsch; Caroline Happold; Norbert Galldiks; Friederike Schmidt-Graf; Michael Bamberg; Guido Reifenberger; Michael Platten; Andreas von Deimling; Christoph Meisner; Benedikt Wiestler; Michael Weller Journal: Neuro Oncol Date: 2016-07-01 Impact factor: 12.300